These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 37952003)
1. Enhancing breadth and durability of humoral immune responses in non-human primates with an adjuvanted group 1 influenza hemagglutinin stem antigen. Swart M; Kuipers H; Milder F; Jongeneelen M; Ritschel T; Tolboom J; Muchene L; van der Lubbe J; Izquierdo Gil A; Veldman D; Huizingh J; Verspuij J; Schmit-Tillemans S; Blokland S; de Man M; Roozendaal R; Fox CB; Schuitemaker H; Capelle M; Langedijk JPM; Zahn R; Brandenburg B NPJ Vaccines; 2023 Nov; 8(1):176. PubMed ID: 37952003 [TBL] [Abstract][Full Text] [Related]
2. Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates. Darricarrère N; Qiu Y; Kanekiyo M; Creanga A; Gillespie RA; Moin SM; Saleh J; Sancho J; Chou TH; Zhou Y; Zhang R; Dai S; Moody A; Saunders KO; Crank MC; Mascola JR; Graham BS; Wei CJ; Nabel GJ Sci Transl Med; 2021 Mar; 13(583):. PubMed ID: 33658355 [TBL] [Abstract][Full Text] [Related]
3. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses. Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203 [TBL] [Abstract][Full Text] [Related]
4. Bivalent H1 and H3 COBRA Recombinant Hemagglutinin Vaccines Elicit Seroprotective Antibodies against H1N1 and H3N2 Influenza Viruses from 2009 to 2019. Allen JD; Ross TM J Virol; 2022 Apr; 96(7):e0165221. PubMed ID: 35289635 [TBL] [Abstract][Full Text] [Related]
6. Squalene-adjuvanted H7N9 virus vaccine induces robust humoral immune response against H7N9 and H7N7 viruses. Wu CY; Chang CY; Ma HH; Wang CW; Chen YT; Hsiao PW; Chang CC; Chan CH; Liu CC; Chen JR Vaccine; 2014 Jul; 32(35):4485-4494. PubMed ID: 24962757 [TBL] [Abstract][Full Text] [Related]
7. Mini-HA Is Superior to Full Length Hemagglutinin Immunization in Inducing Stem-Specific Antibodies and Protection Against Group 1 Influenza Virus Challenges in Mice. van der Lubbe JEM; Verspuij JWA; Huizingh J; Schmit-Tillemans SPR; Tolboom JTBM; Dekking LEHA; Kwaks T; Brandenburg B; Meijberg W; Zahn RC; Roozendaal R; Kuipers H Front Immunol; 2018; 9():2350. PubMed ID: 30369928 [TBL] [Abstract][Full Text] [Related]
11. Conformational Stability of the Hemagglutinin of H5N1 Influenza A Viruses Influences Susceptibility to Broadly Neutralizing Stem Antibodies. Wang W; Song HS; Keller PW; Alvarado-Facundo E; Vassell R; Weiss CD J Virol; 2018 Jun; 92(12):. PubMed ID: 29593038 [TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. Hehme N; Engelmann H; Kuenzel W; Neumeier E; Saenger R Virus Res; 2004 Jul; 103(1-2):163-71. PubMed ID: 15163505 [TBL] [Abstract][Full Text] [Related]
13. Elicitation of Protective Antibodies against 20 Years of Future H3N2 Cocirculating Influenza Virus Variants in Ferrets Preimmune to Historical H3N2 Influenza Viruses. Allen JD; Jang H; DiNapoli J; Kleanthous H; Ross TM J Virol; 2019 Feb; 93(3):. PubMed ID: 30429350 [TBL] [Abstract][Full Text] [Related]
14. Tuning the immune response: sulfated archaeal glycolipid archaeosomes as an effective vaccine adjuvant for induction of humoral and cell-mediated immunity towards the SARS-CoV-2 Omicron variant of concern. Renner TM; Akache B; Stuible M; Rohani N; Cepero-Donates Y; Deschatelets L; Dudani R; Harrison BA; Baardsnes J; Koyuturk I; Hill JJ; Hemraz UD; Régnier S; Lenferink AEG; Durocher Y; McCluskie MJ Front Immunol; 2023; 14():1182556. PubMed ID: 37122746 [TBL] [Abstract][Full Text] [Related]
17. Characterization of humoral and cell-mediated immunity induced by mRNA vaccines expressing influenza hemagglutinin stem and nucleoprotein in mice and nonhuman primates. Flynn JA; Weber T; Cejas PJ; Cox KS; Touch S; Austin LA; Ou Y; Citron MP; Luo B; Gindy ME; Bahl K; Ciaramella G; Espeseth AS; Zhang L Vaccine; 2022 Jul; 40(32):4412-4423. PubMed ID: 35680500 [TBL] [Abstract][Full Text] [Related]
18. Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial. Jackson LA; Campbell JD; Frey SE; Edwards KM; Keitel WA; Kotloff KL; Berry AA; Graham I; Atmar RL; Creech CB; Thomsen IP; Patel SM; Gutierrez AF; Anderson EL; El Sahly HM; Hill H; Noah DL; Bellamy AR JAMA; 2015 Jul; 314(3):237-46. PubMed ID: 26197184 [TBL] [Abstract][Full Text] [Related]
19. A Bivalent Heterologous DNA Virus-Like-Particle Prime-Boost Vaccine Elicits Broad Protection against both Group 1 and 2 Influenza A Viruses. Jiang W; Wang S; Chen H; Ren H; Huang X; Wang G; Chen Z; Chen L; Chen Z; Zhou P J Virol; 2017 May; 91(9):. PubMed ID: 28179535 [TBL] [Abstract][Full Text] [Related]
20. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice. Goff PH; Hayashi T; He W; Yao S; Cottam HB; Tan GS; Crain B; Krammer F; Messer K; Pu M; Carson DA; Palese P; Corr M J Virol; 2017 Oct; 91(19):. PubMed ID: 28724768 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]